CARMA3/NF-κB signaling contributes to tumorigenesis of hepatocellular carcinoma and is inhibited by sodium aescinate

Table 1 Relationship between CARMA3 expression and clinical characteristics of hepatocellular carcinoma patients

Clinical characteristic	All samples (n = 100)	High expression	Low expression	P-value
Gender				0.882
Female	11	7	4
Male	89	50	39
Age (yr)				0.435
< 52	49	26	23
> 52	51	31	20
AFP (ng/mL)				0.424
Positive (> 20 ng/mL)	63	34	29
Negative (< 20 ng/mL)	37	23	14
Cirrhosis				0.640
Yes	72	40	32
No	28	17	11
HBV				0.657
Yes	65	36	29
No	35	21	14
Child-Pugh				0.986
A	94	54	40
B	6	4	2
Microvascular invasion				0.666
Yes	28	15	13
No	72	42	30
TNM stage				0.008
I	35	15	20
II	28	20	18
III-IV	27	22	5
Differentiation				0.004
Poor	25	19	6
Moderate	41	26	15
Well	34	12	22
Tumor number				0.120
Single	87	47	40
Multiple	13	10	3
Tumor size				0.014
< 5 cm	40	16	24
> 5 cm, < 10 cm	36	23	13
> 10 cm	24	18	6

AFP: Alpha-fetoprotein.